Keep Health Economics Groups Out of Information Silos

Jacob Presson, health economics groups researcher
By Jacob Presson,
Senior Research Analyst

One of the major organizational challenges presented by health economics groups is the fact that they need data from the clinical and scientific side of the organization in order to make an effective case for payers that may be used to speaking with the commercial side of the company.  This issue is part of why many health economics groups report into medical affairs so that they can preserve their scientific expertise and credibility while bridging the gap to payers as needed. Continue reading

Protecting Profitability: Translating Strong HEOR to Drive Interactions with Medical Device Payers and More

Victoria Cavicchi, pharmaceutical social media researcher
By Victoria Cavicchi,
Research Analyst

Health economics and outcomes research (HEOR) groups have carved out their place in life sciences organizations throughout the industry. Though pharmaceutical and biotech companies have long-since accepted the utility of this function, many medical device HEOR efforts have leveraged other groups to perform HEOR tasks — often ad hoc. Now, HEORs’ prominence is more widespread, and device companies are structuring health economics staff to take on a number of reimbursement-related responsibilities. One of these teams’ most prominent activities is aiding interactions with government and private medical device payers. Continue reading

Drug Safety Data and HEOR Driving Clinical Trial Costs and Time

Ryan McGuire, lifecycle management tactics expert
By Ryan McGuire,
Research Analyst

The healthcare marketplace has seen seismic shifts over the past five years.  Austerity measures have strained the reimbursement climate in many EU countries and driven government payers to scrutinize every new drug as never before.  Healthcare reform in the United States has the potential to add coverage for 30 million uninsured Americans.  As a result, pharmaceutical companies are working even harder to gain favorable formulary placement with private payers. Continue reading

A Method to the Madness: Maximizing Managed Markets Account Managers Interactions with Payers

Jacob Presson, pharmaceutical market access researcher
By Jacob Presson,
Senior Research Analyst

As payers demand ever-increasing evidence of product efficacy and cost effectiveness from the pharmaceutical industry, managing relationships with them is growing in strategic importance.  As a result, account managers dedicated to delivering the right kind of data to payers are becoming more vital.  What do pharma companies need to do to maximize this interaction? Continue reading

HEORs and Tails: Why Is Staffing Market Access Teams So Difficult?

Pharmaceutical market access teams hold a wide range of responsibilities and, as such, require employees with a variety of knowledge and skills.  Organizations that create a well-rounded market access team can work with payers better to achieve an optimal reimbursement amount and stay competitive in the marketplace.  Finding these employees is much easier said than done, however.  Half of companies surveyed for a new report ranked finding skilled employees as either challenging or very challenging (Figure 1).  Pharmaceutical market access groups have only one primary goal (among a number of secondary goals): to achieve reimbursement.  Why do the people for this job need to be so multi-talented?  Continue reading

HEOR ROI: Making Health Economics and Outcomes Research an Outcomes-Based Function

Over the past 18 months, the Cutting Edge Information research team has conducted several studies related to the life sciences industry’s drive to improve market access. We’ve put together reports on health economics and outcomes research (HEOR) teams, pricing groups, health outcomes field forces and overall market access management. Through all the studies, one theme has risen to the top — health outcomes and economic data is critical to market access Continue reading

Market Access Budgets Rebound After 2012 Patent Cliff

By Natalie DeMasi,
Research Analyst

In 2012, many key drugs in the US fell off the patent cliff and lost their market exclusivity.  As US pharmaceutical companies watched these products meet their fates, they tried their best to mitigate the damage.  Some companies have decreased reliance on blockbuster drugs by diversifying their pipelines.  Others have looked to mergers or entered the generics market themselves.  In the end, however, most companies had to simply brace themselves and cut their losses.  For market access, these methods resulted in decreased budgets for 2012. Continue reading